. Author manuscript; available in PMC: 2022 Sep 5.

Published in final edited form as: Lancet Glob Health. 2020 Jan 1;8(1):e92–e100. doi: 10.1016/S2214-109X(19)30453-X

Table 1. Summary of included studies for the quantitative analysis.

	Study design	Country	Inadvertent treatment	Concomitant albendazole	Gestational period	Spontaneous abortions and stillbirths		Congenital anomalies
	Study design	Country	Inadvertent treatment	Concomitant albendazole	Gestational period	Ivermectin-exposed group	Control group	Ivermectin-exposed group	Control group
Chippaux et al (1993)³²	Retrospective case-control study	Cameroon	Yes, during MDA programme	No	First trimester*	21/111	53/404	0/111	2/404
Doumbo et al (1992)³³	Retrospective case-control study	Mali	Yes, during MDA programme	No	Unclear	3/82	6/139	0/82	1/139
Gyapong et al (2003)³⁴	Retrospective case-control study	Ghana	Yes, during MDA programme	Yes	Unclear	2/50	21/293	1/50	5/293
Makene et al (2003)³⁵	Retrospective case-control study	Tanzania	Yes, during MDA programme	Yes	Unclear	NA	NA	6/54	4/63
Ndyomugyenyi et al (2008)³⁶	Open-label randomised controlled trial	Uganda	No	Yes	Second and third trimester	4/399	7/438	1/399	1/438
Pacque et al (1990)¹³	Retrospective case-control study	Liberia	Yes, during MDA programme	No	Unclear	5/203	55/1767	5/203	21/1767

Data are n/N, unless otherwise specified. MDA=mass drug administration. NA=not available. *97 of 110 were exposed during the first trimester of pregnancy; the remaining 13 were not specified. These 110 exposures generated 111 pregnancy outcomes.